Intel Group (000411): foreign Investment rating report (overseas institutions Investment rating D)
Intel Group (000411) report comments: steady income growth and the dust of the actual controller has settled.
Intel Group (000411) Annual report comments: performance growth exceeding expectations or ushering in a new situation of development
Intel Group (000411) report comments: steady performance growth is expected to benefit from asset restructuring and "two-vote system"
Inter Group (000411) Review: Joining forces with Zhuojian Technology to lay out Internet+medical treatment, and Intel Pharmaceutical's injection is progressing steadily
[Huachuang Securities] Intel Group: Light weight, fresh start
Intel Group (000411) Research brief: light to start again
Intel Group (000411) brief: Zhejiang Pharmaceutical Business leaders set sail again
[Guojin Securities] Intel Group: Zhejiang Pharmaceutical Commercial Leader set sail again
[Aijian Securities] Research report of Intel Group: intensive cultivation of Zhejiang pharmaceutical commercial market, broad prospects for development
[Qunyi Securities (Hong Kong)] Intel Group: Zhejiang pharmaceutical distribution giant with good fundamentals
[Oriental Securities] Intel Group: Strong software and hardware strength, strives for regional leadership
[Xiangcai Securities] Intel Group Annual Report Review: Commercial Mergers and Acquisitions and Internet Downturn Boost Performance
[Xiangcai Securities] Intel Group: Full coverage in the province is beginning to take shape, and subsequent integration highlights performance flexibility
[Guodu Securities] Intel Group: Joins Hays Pharmaceuticals and advances into southwestern Zhejiang
[Xiangcai Securities] Intel Group: Inter Pharmaceutical Acquires Wenzhou Supply and Marketing Reviews
[Xiangcai Securities] Intel Group: Expanding the Chinese Medicine Industry, Differentiated Competition Strategy Is Clear
[GF Securities] Intel Group: Property Asset Sales Are Moving Forward, Pricing Exceeds Expectations
[GF Securities] Intel Group: High-Quality Regional Pharmaceutical Business Leader with Insufficient Market Awareness
[Xiangcai Securities] Intel Group: Distribution, mergers and restructuring are accelerating, and the company's performance is flexible
No Data